54 medicines will see only 1 paisa hike: Health Ministry after media reports on drug price hike
New Delhi: Responding to several media reports about the price rise of essential medicines from April 1, 2024, the Ministry of Health and Family Welfare has come out with a statement calling many reports claiming medicine prices to witness a significant hike by up to 12% from April, 2024 as false, misleading and malicious.
The ministry has clarified that of the 923 formulations which fall under the ceiling price, 728 will see no change in prices while 54 will see a price rise of merely one paisa.
"Some media reports have highlighted that medicine prices will witness a significant hike by up to 12% from April, 2024. These reports further claim that more than 500 medicines will be affected by this increase in price. Such reports are false, misleading and malicious," the Ministry informed.
As per the provisions of Drug Price Control Orders (DPCO) 2013, drugs are categorized as scheduled and non-scheduled formulations. The formulations which are listed in Schedule-I of DPCO 2013 are scheduled formulations and the formulations that are not specified in Schedule-I of DPCO 2013 are non-schedule formulations. National Pharmaceutical Pricing Authority (NPPA) under the Department of Pharmaceuticals annually revises the ceiling prices of scheduled medicines on the basis of Wholesale Price Index (WPI). The scheduled medicines included in the Schedule-I of the DPCO, 2013 are essential medicines.
"During the calendar year 2023 over the corresponding period in 2022, the annual change in WPI with base year 2011-12 was (+) 0.00551% as per data published by Department for Promotion of Industry and Internal Trade (DPIIT). Accordingly, the Authority in its meeting held on 20.03.2024 has approved the WPI increase @ (+) 0.00551% for the scheduled medicines," Health Ministry stated.
"The ceiling prices on 923 medicines are effective as on date. Based on the above mentioned WPI factor of (+) 0.00551%, there will be no change in the prevailing ceiling prices for 782 medicines and the existing ceiling prices will continue to prevail up to 31.03.2025. Fifty-Four (54) medicines with ceiling price ranging from Rs. 90 to Rs. 261 will have a miniscule increase of Rs. 0.01(one paisa). As the permissible price increase is miniscule, the companies may or may not avail this increase. Thus, in the year FY 2024-25, there will be almost no change in the ceiling price of medicines based on WPI," it noted.
"The WPI increase is the maximum increase permissible as per the DPCO, 2013 and the manufacturers may or may not avail this increase, keeping in view the market dynamics. The companies adjust their Maximum Retail Price (MRP) depending upon the ceiling price of their medicines, as MRP (excluding GST) can be any price which is less than the ceiling price. The revised prices will be applicable from 1st April 2024 and the detail of revised prices is available on NPPA’s website," it added.
In case of non-scheduled formulation, a manufacturer is at liberty to fix the price. However, no manufacturer of non-scheduled formulation can increase the MRP by more than 10% during preceding 12 months under Para 20 of DPCO, 2013.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.